Pharnext logo

Pharnext unveils the latest progress of the PREMIER Phase III clinical trial for CMT1A

by | Mar 6, 2023 | 0 comments

The PREMIER trial, initiated in March 2021, is an international, randomized, double-blind, two-arm placebo-controlled, pivotal Phase III study, where the primary objective is to evaluate the efficacy and safety of PXT3003 versus placebo in mild-to-moderate CMT1A patients, over a 15-month period. The dose of PXT3003 tested in the PREMIER trial corresponds to the high dose (HD) tested in the prior Phase III clinical study, the PLEO-CMT trial, and its ongoing open-label extension Phase III study, the PLEOCMT-FU trial. As agreed with regulatory agencies, the primary efficacy endpoint will be the Overall Neuropathy Limitations Scale (‘ONLS’) which measures functional motor disability. A total of 387 patients with mild-to-moderate CMT1A, was enrolled in the PREMIER trial (exceeding the initial enrolment target of 350 subjects as defined in the study protocol): 153 in the United States, 183 in Europe, 39 in Canada and 12 in Israel.

The 15-month double-blind phase of the PREMIER trial is followed by an open-label extension phase named PREMIEROLE (Open Label Extension). All patients who completed the double-blind phase of the PREMIER trial are eligible to join the open-label extension phase, PREMIER-OLE, and have the opportunity to receive PXT3003 HD until the treatment is commercially available, should PXT3003 be approved in the US and Europe, respectively by the FDA and the EMA. The first patient entered the PREMIER-OLE phase in September 2022.

Furthermore, Pharnext successfully completed the manufacturing transfer and scale-up of PXT3003 from Unither’s facility in Colomiers, France, to Unither’s U.S.A. facility in Rochester, New York to prepare for potential marketing authorization of PXT3003. PXT3003 is now able to be manufactured in batches of up to 3,500 liters of oral solution, a volume potentially compatible with a commercial supply chain of PXT3003 enabling a more convenient and flexible form for CMT1A patients to use, allowing for better compliance.

The topline results announcement of this study is planned in Q4 2023

Learn more on this topic

Related Blog Posts

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Targeting PMP22 in CMT1A Patients with Gene Duplication

In previous collaborative work with a group of investigators including Dr Rolf Renne from the University of Florida, Dr. Alex Murashov from East Carolina University and Dr. Lynn Hudson from the NIH-NINDS, we validated a microRNA known as miR29a as a reagent that corrected the expression level of PMP22 in rodent Schwann cells.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news